

Electronic Supplementary Information

Synthesis and Biocompatibility Evaluation of Fluorinated, Single-tailed Glucopyranoside Surfactants

Xueshu Li,^a Jaroslav Turánek,^b Pavlína Knötigová,^b Hana Kudláčková,^b Josef Mašek,^b D Brant Pennington,^c Stephen E Rankin,^c Barbara L Knutson^c and Hans-Joachim Lehmler*^a

^a Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA, 52242, USA. Fax: 3193354290; Tel: 3193354211; ^b Veterinary Research Institute v.v.i., Department of Vaccinology and Immunotherapy, Brno, Czech Republic; ^c Chemicals and Materials Engineering Department, University of Kentucky, Lexington, KY, 40506, USA.

CONTENT: Detailed characterization of compounds **6b**, **6c**, **6e**, **6f**, **7b**, **7c**, **7e**, **7f**, **8b**, **8c**, **8e**, **8f**, **9b**, **9c**, **9e** and **9f**.

11,11,12,12,13,13,14,14,15,15,16,16,16-Tridecafluorohexadecyl-2,3,4,6-tetra-O-acetyl- β -D-glucopyranoside (6b):

White solid; mp: 53-54 °C; Yield, 53%; ^1H NMR (400 MHz, CDCl_3): δ/ppm 1.1-1.4 (m, 12H, $6\times\text{CH}_2$), 1.57 (m, 4H, H-2' and H-9'), 1.9-2.0 (m, 14H, $4\times\text{CH}_3\text{CO}$ and H-10'), 3.45 (m, 1H, H-1'a), 3.68 (m, 1H, H-5), 3.86 (m, 1H, H-1'b), 4.12 (d, 1H, $J_{6a,6b} = 12.3$ Hz, H-6a), 4.25 (dd, 1H, $J_{6a,6b} = 12.3$ Hz, $J_{5,6b} = 4.7$ Hz, H-6b), 4.47 (d, 1H, $J_{1,2} = 8.0$ Hz, H-1), 4.97 ("t", 1H, $J \sim 8.4$ Hz, H-2), 5.08 ("t", 1H, $J \sim 8.6$ Hz, H-4), 5.16 ("t", 1H, $J \sim 8.4$ Hz, H-3). ^{13}C NMR (100 MHz, CDCl_3): δ/ppm 20.1 (C-9'), 20.8 ($4\times\text{CH}_3\text{CO}$), 25.9 (C-3'), 29.3-29.7 (C-2', C-4' to C-8'), 31.0 (t, $J = 23$ Hz, C-10'), 62.1 (C-6), 68.6 (C-4), 70.4 (C-1'), 71.5 (C-2), 71.9 (C-5), 73.0 (C-3), 101.0 (C-1), 169.5, 169.6, 170.5, 170.9 ($4\times\text{COCH}_3$). ^{19}F NMR δ/ppm (282 MHz, CDCl_3): -81.3 (CF_3), -114.9 (CF_2), -122.5 (CF_2), -123.4 (CF_2), -124.1 (CF_2), -126.7 (CF_2). Positive-ion ESI-MS peak at m/z 829 ($[\text{M}+\text{Na}]^+$).

11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,18-Heptadecafluoroctadecyl-2,3,4,6-tetra-O-acetyl- β -D-glucopyranoside (6c):

White solid; mp: 75-76 °C; Yield, 55%; ^1H NMR (300 MHz, CDCl_3): δ/ppm 1.1-1.4 (m, 12H, $6\times\text{CH}_2$), 1.53 (m, 4H, H-2' and H-9'), 1.9-2.1 (m, 14H, $4\times\text{CH}_3\text{CO}$ and H-10'), 3.41 (m, 1H, H-1'a), 3.66 (ddd, 1H, $J_{4,5} = 9.8$ Hz, $J_{5,6a} = 2.5$ Hz, $J_{5,6b} = 4.6$, H-5), 3.83 (m, 1H, H-1'b), 4.09 (dd, 1H, $J_{6a,6b} = 12.2$ Hz, $J_{5,6a} = 2.4$ Hz, H-6a), 4.24 (dd, 1H, $J_{6a,6b} = 12.2$ Hz, $J_{5,6b} = 4.7$ Hz, H-6b), 4.45 (d, 1H, $J = 8.0$ Hz, H-1), 4.95 (dd, 1H, $J_{1,2} = 8.0$ Hz, $J_{2,3} = 9.4$ Hz, H-2), 5.05 ("t", 1H, $J \sim 9.6$ Hz, H-4), 5.17 ("t", 1H, $J \sim 9.4$ Hz, H-3). ^{13}C NMR (75 MHz, CDCl_3): δ/ppm 20.2 (C-9'), 20.7 ($4\times\text{CH}_3\text{CO}$), 25.9 (C-3'), 29.2-29.6 (C-2', C-4' to C-8'), 30.9 (t, $J = 21$ Hz, C-10'), 62.1 (C-6), 68.6 (C-4), 70.4 (C-1'), 71.5 (C-2), 71.9 (C-5), 73.0 (C-3), 101.0 (C-1), 169.4,

169.5, 170.4, 170.8 ($4\times\text{COCH}_3$). ^{19}F NMR δ/ppm (282 MHz, CDCl_3): CDCl_3 -81.5 (CF_3), -115.1 (CF_2), -122.3 ($3\times\text{CF}_2$), -123.3 (CF_2), -124.1 (CF_2), -126.7 (CF_2). Positive-ion ESI-MS peak at m/z 929 ($[\text{M}+\text{Na}]^+$).

12,12,13,13,14,14,15,15,16,16,17,17,17-Tridecafluoroheptadecyl-2,3,4,6-tetra-O-acetyl- β -D-glucopyranoside (6e): White solid; mp: 61-62 °C; Yield, 46%; ^1H NMR (400 MHz, CDCl_3): δ/ppm 1.1-1.4 (m, 14H, $7\times\text{CH}_2$), 1.56 (m, 4H, H-2' and H-10'), 1.9-2.1 (m, 14H, $4\times\text{CH}_3\text{CO}$ and H-11'), 3.46 (m, 1H, H-1'a), 3.67 (ddd, 1H, $J_{4,5} = 9.8$ Hz, $J_{5,6a} = 2.5$ Hz, $J_{5,6b} = 4.6$, H-5), 3.84 (m, 1H, H-1'b), 4.11 (m, 1H, H-6a), 4.25 (dd, 1H, $J_{6a,6b} = 12.3$ Hz, $J_{5,6b} = 4.8$ Hz, H-6b), 4.47 (d, 1H, $J = 8.0$ Hz, H-1), 4.96 (dd, 1H, $J_{1,2} = 7.9$ Hz, $J_{2,3} = 9.5$ Hz, H-2), 5.06 ("t", 1H, $J \sim 9.7$ Hz, H-4), 5.19 ("t", 1H, $J \sim 9.4$ Hz, H-3). ^{13}C NMR (100 MHz, CDCl_3) δ/ppm 20.4 (C-10'), 20.7-20.8 ($4\times\text{CH}_3\text{CO}$), 26.0 (C-3'), 29.3-29.7 (C-2', C-4' to C-9'), 31.2 (t, $J = 22$ Hz, C-11'), 62.4 (C-6), 69.0 (C-4), 70.3 (C-1'), 71.8 (C-2), 72.1 (C-5), 73.2 (C-3), 101.1 (C-1), 169.3, 169.5, 170.4, 170.7 ($4\times\text{COCH}_3$). ^{19}F NMR (282 MHz, CDCl_3): δ/ppm -81.3 (CF_3), -114.9 (CF_2), -122.5 (CF_2), -123.4 (CF_2), -124.1(CF_2), -126.7 (CF_2). Positive-ion ESI-MS peak at m/z 843 ($[\text{M}+\text{Na}]^+$).

12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,19-Heptadecafluorononadecyl-2,3,4,6-tetra-O-acetyl-D-glucopyranoside (6f): White solid; mp: 76-77 °C; Yield, 52 %; ^1H NMR (300 MHz, CDCl_3): δ/ppm 1.2-1.4 (m, 14H, -(CH_2CH_2)₇), 1.60 (m, 4H, H-2' and H-10'), 1.9-2.1 (m, 14H, $4\times\text{CH}_3\text{CO}$ and H-11'), 3.47 (m, 1H, H-1'a), 3.70 (m, 1H, H-5), 3.86 (m, 1H, H-1'b), 4.0-4.14 ("d", 1H, H-6a), 4.26 (dd, 1H, $J_{6a,6b} = 12.0$ Hz, $J_{5,6b} = 4.5$ Hz, H-6b), 4.48 (d, 1H, $J = 7.9$ Hz, H-1), 4.98 ("t", 1H, $J \sim 8.5$ Hz, H-2), 5.08 ("t", 1H, J

~9.6 Hz, H-4), 5.20 (“t”, 1H, $J \sim 9.6$ Hz, H-3). ^{13}C NMR (75 MHz, CDCl_3) δ/ppm 20.3 (CH₂-10'), 20.8-20.9 (4×CH₃CO), 26.0 (C-3'), 29.3-29.7 (7×CH₂, 2', 4'-9'), 31.1 (t, $J = 22$ Hz, C-11'), 62.2 (C-6), 68.7 (C-4), 70.4 (C-1'), 71.6 (C-2), 71.9 (C-5), 73.1 (C-3), 101.1 (C-1), 169.5, 169.6, 170.5, 170.9 (4×COCH₃). ^{19}F NMR (282 MHz, CDCl_3): δ/ppm -81.3 (CF₃), -114.9 (CF₂), -122.5 (3×CF₂), -123.4 (CF₂), -124.1 (CF₂), -126.7 (CF₂). Positive-ion ESI-MS peak at m/z 943 ([M+Na]⁺).

Hexadecyl-2,3,4,6-tetra-O-acetyl- β -D-glucopyranoside (7b)⁶

White solid; mp: 67-68 °C (Lit.: 70-73.5^{1,2} °C, 90-92 °C³); Yield, 49%; ^1H NMR (300 MHz, CDCl_3): δ/ppm 0.88 (t, 3H, $J = 7.0$ Hz, H-16'), 1.1-1.4 (m, 26H, 13×CH₂), 1.57 (m, 2H, H-2'), 1.9-2.1 (4×s, 12H, 4×CH₃CO), 3.48 (dt, 1H, $J_{I'a,I'b} = 9.4$ Hz, $J_{I'a,2'} = 6.7$ Hz, H-1'a), 3.70 (ddd, 1H, $J_{4,5} = 9.9$ Hz, $J_{5,6a} = 2.5$ Hz, $J_{5,6b} = 4.7$, H-5), 3.87 (dt, 1H, $J_{I'a,I'b} = 9.4$ Hz, $J_{I'b,2'} = 6.7$ Hz, H-1'b), 4.13 (dd, 1H, $J_{6a,6b} = 12.3$ Hz, $J_{6a,5} = 2.5$ Hz, H-6a), 4.26 (dd, 1H, $J_{6a,6b} = 12.3$ Hz, $J_{5,6b} = 4.7$ Hz, H-6b), 4.48 (d, 1H, $J_{1,2} = 8.0$ Hz, H-1), 4.98 (dd, 1H, $J_{1,2} = 8.0$ Hz, $J_{2,3} = 9.5$ Hz, H-2), 5.09 (“t”, 1H, $J \sim 9.7$ Hz, H-4), 5.21 (“t”, 1H, $J \sim 9.5$ Hz, H-3). ^{13}C NMR (75 MHz, CDCl_3): δ/ppm 14.3 (C-16'), 20.8-20.9 (4×CH₃CO), 22.9 (C-15'), 26.1 (C-3'), 29.5-29.9 (C-2', C-4' to C-13'), 32.1 (C-14'), 62.2 (C-6), 68.7 (C-4), 70.5 (C-1'), 71.6 (C-2), 71.9 (C-5), 73.0 (C-3), 101.0 (C-1), 169.5, 169.6, 170.5, 170.9 (4×COCH₃). Positive-ion ESI-MS peak at m/z 595 ([M+Na]⁺).

Octadecyl 2,3,4,6-tetra-O-acetyl- β -D-glucopyranoside (7c)

White solid; mp: 76-77 °C (Lit.: 78-79.5 °C¹) Yield, 48%; ^1H NMR (300 MHz, CDCl_3): δ/ppm 0.88 (t, 3H, $J = 7.0$ Hz, H-18'), 1.1-1.4 (m, 30H, 15×CH₂), 1.56 (m, 2H, H-2'),

2.0-2.1 (4×s, 12H, 4×CH₃CO), 3.47 (dt, 1H, J_{1'a,1'b} = 9.5 Hz, J_{1'a,2'} = 6.7 Hz, H-1'a), 3.69 (ddd, 1H, J_{4,5} = 9.8 Hz, J_{5,6a} = 2.5 Hz, J_{5,6b} = 4.8, H-5), 3.85 (dt, 1H, J_{1'a,1'b} = 9.5 Hz, J_{1'b,2'} = 6.7 Hz, H-1'b), 4.13 (dd, 1H, J_{6a,6b} = 12.3 Hz, J_{6a,5} = 2.5 Hz, H-6a), 4.25 (dd, 1H, J_{6a,6b} = 12.3 Hz, J_{5,6b} = 4.8 Hz, H-6b), 4.48 (d, 1H, J_{1,2} = 7.9 Hz, H-1), 4.97 (dd, 1H, J_{1,2} = 7.9 Hz, J_{2,3} = 9.5 Hz, H-2), 5.08 ("t", 1H, J ~ 9.8 Hz, H-4), 5.20 ("t", 1H, J ~ 9.4 Hz, H-3). ¹³C NMR (75 MHz, CDCl₃): δ/ppm 14.3 (C-18'), 20.8-20.9 (4×CH₃CO), 22.9 (C-17'), 26.1 (C-3'), 29.6-29.9 (C-2', C-4' to C-15'), 32.2 (C-16'), 62.3 (C-6), 68.9 (C-4), 70.5 (C-1'), 71.7 (C-2), 72.1 (C-5), 73.2 (C-3), 101.1 (C-1), 169.4, 169.6, 170.5, 170.8 (4×COCH₃). Positive-ion ESI-MS peak at m/z 623 ([M+Na]⁺).

Heptadecyl 2,3,4,6-tetra-O-acetyl- β-D-glucopyranoside (7e): White solid; mp: 75-76 °C; Yield, 50 %; ¹H NMR (300 MHz, CDCl₃): δ/ppm 0.88 (t, 3H, J = 7.0 Hz, H-17'), 1.2-1.3 (m, 28H, 14×CH₂), 1.56 (m, 2H, H-2'), 2.0-2.1 (4×s, 12H, 4×CH₃CO), 3.48 (dt, 1H, J_{1'a,1'b} = 9.7 Hz, J_{1'a,2'} = 6.7 Hz, H-1'a), 3.68 (ddd, 1H, J_{4,5} = 9.9 Hz, J_{5,6a} = 2.6 Hz, J_{5,6b} = 4.8, H-5), 3.86 (dt, 1H, J_{1'a,1'b} = 9.7 Hz, J_{1'a,2'} = 6.7 Hz, H-1'b), 4.14 (dd, 1H, J_{6a,6b} = 12.3 Hz, J_{6a,5} = 2.5 Hz, H-6a), 4.26 (dd, 1H, J_{6a,6b} = 12.3 Hz, J_{5,6b} = 4.8 Hz, H-6b), 4.49 (d, 1H, J_{1,2} = 8.0 Hz, H-1), 4.98 (dd, 1H, J_{1,2} = 7.9 Hz, J_{2,3} = 9.5 Hz, H-2), 5.08 ("t", 1H, J ~ 9.7 Hz, H-4), 5.21 ("t", 1H, J ~ 9.5 Hz, H-3). ¹³C NMR (75 MHz, CDCl₃): δ/ppm 14.3 (C-17'), 20.8-21.0 (4×CH₃CO), 22.9 (C-16'), 26.0 (C-3'), 29.5-29.9 (C-2', C-4' to C-14'), 32.2 (C-15'), 62.2 (C-6), 68.7 (C-4), 70.5 (C-1'), 71.6 (C-2), 72.0 (C-5), 73.1 (C-3), 101.1 (C-1), 169.5, 169.6, 170.5, 170.9 (4×COCH₃). Positive-ion ESI-MS peak at m/z 609 ([M+Na]⁺).

Nonadecyl 2,3,4,6-tetra-O-acetyl-(α + β)-D-glucopyranoside (7f): White solid; mp: 69-71°C (1:4 mixture of the α - and β -anomer); Yield, 52%; ^1H NMR (400 MHz, CDCl_3): δ/ppm 0.8-0.9 (t, 3H, $J = 7.0$ Hz, H-19'), 1.1-1.4 (m, 32H, 16 \times CH_2), 1.60 (m, 2H, CH₂-2'), 1.9-2.2 (m, 12H, 4 \times CH_3CO), 3.48 (m, 1H, H-1' α a and H-1' β a), 3.6-3.7 (m, H-1' β a and H-5 β), 3.83 (m, H-1' b β), 3.9-4.2 (m, H-4 α , H-5 α , H-6a β), 4.2-4.3 (m, H-6aa, H-6b β), 4.45 (d, $J_{1,2} = 7.9$ Hz, H-1 β), 4.81 (d, H-6ba), 4.9-5.1 (m, H-2 α , H-3 α , H-2 β , H-4 β), 5.15 (t, $J \sim 9.5$ Hz, H-3 β), 5.43 (t, $J = 9.4$ Hz, H-1 α). ^{13}C NMR (100 MHz, CDCl_3) δ/ppm typical signal of α and β -anomer: 95.7 (C-1 α), 100.9 (C-1 β). Positive-ion ESI-MS peak at m/z 637 ($[\text{M}+\text{Na}]^+$).

11,11,12,12,13,13,14,14,15,15,16,16,16-Tridecafluorohexadecyl- β -D-glucopyranoside (8b): White solid; mp: 70-72 °C; mp(DSC): 68.87 ± 0.57 °C, 161.92 ± 1.08 °C; Yield, 93%; ^1H NMR (300 MHz, CD_3OD): δ/ppm 1.3-1.5 (m, 12H, 6 \times CH_2), 1.6-1.7 (m, 4H, H-2' and H-9'), 2.15 (m, 2H, H-10'), 3.20 ("t", 1H, $J \sim 8.1$ Hz, H-2), 3.2-3.4 (m, 3H, H-3, H-4 and H-5), 3.57 (m, 1H, H-1' α), 3.66 (dd, 1H, $J_{6a,6b} = 11.9$ Hz, $J_{5,6a} = 5.0$ Hz, H-6a), 3.8-4.0 (m, 2H, H-6b and H-1' b), 4.28 (d, 1H, $J_{1,2} = 7.7$ Hz, H-1). ^{13}C NMR (75 MHz, CD_3OD) δ/ppm 21.4 (C-9'), 27.3 (C-3'), 30.3-30.9 (C-2', C-4' to C-8'), 31.9 (t, $J = 22$ Hz, C-10'), 62.9 (C-6), 71.0 (C-1'), 71.7 (C-4), 75.2 (C-2), 78.0 (C-5), 78.2 (C-3), 104.5 (C-1). ^{19}F NMR (282 MHz, CD_3OD) δ/ppm -80.7 (CF₃), -113.8 (CF₂), -121.3 (CF₂), -122.3 (CF₂), 122.9 (CF₂), 125.7 (CF₂). Anal. calcd. for $\text{C}_{22}\text{H}_{31}\text{F}_{13}\text{O}_6$: C 41.39, H 4.89. Found: C 41.15, H 4.74. HR-MS of $[\text{M}+\text{Na}]^+$ m/z: Calcd. 661.1811, Found. 661.1811.

11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,18-Heptadecafluoroctadecyl- β -D-glucopyranoside (8c):

White solid; mp: 106-108 °C; mp(DSC): 109.15±1.38 °C, 183.14±0.50 °C; Yield, 96%; ^1H NMR (400 MHz, CD₃OD): δ /ppm 1.3-1.4 (m, 12H, 6×CH₂), 1.6-1.7 (m, 4H, H-2' and H-9'), 2.17 (m, 2H, H-10'), 3.21 (t, 1H, J ~ 8.1 Hz, H-2), 3.3-3.4 (m, 3H, H-3, H-4 and H-5), 3.58 (m, 1H, H-1'a), 3.72 (dd, 1H, $J_{6\text{a},6\text{b}} = 11.8$ Hz, J_{5,6a} = 5.1 Hz, H-6a), 3.8-4.0 (m, 2H, H-6b and H-1'b), 4.28 (d, 1H, $J_{1,2} = 7.7$ Hz, H-1). ^{13}C NMR (75 MHz, CD₃OD) δ /ppm 21.3 (C-9'), 27.1 (C-3'), 30.1-30.9 (C-2', C-4' to C-8'), 31.9 (t, J = 22 Hz, C-10'), 62.9 (C-6), 70.9 (C-1'), 71.8 (C-4), 75.2 (C-2), 77.9 (C-5), 78.3 (C-3), 104.4 (C-1). ^{19}F NMR (282 MHz, CD₃OD) δ /ppm -81.4 (CF₃), -114.9 (CF₂), -122.3 (3×CF₂), -123.3 (CF₂), -124.4 (CF₂), -126.7 (CF₂). Anal. calcd. for C₂₄H₃₁F₁₇O₆: C 39.03, H 4.23. Found: C 39.31, H 4.28. HR-MS of [M+Na]⁺ m/z: Calcd. 761.1747, Found. 761.1760.

12,12,13,13,14,14,15,15,16,16,17,17,17-Tridecafluoroheptadecyl- β -D-glucopyranoside (8e):

White solid; mp: 106-107 °C; mp(DSC): 110.12±0.19 °C, 182.56±0.11 °C; Yield, 95%; ^1H NMR (400 MHz, CD₃OD): δ /ppm 1.3-1.5 (m, 14H, 7×CH₂), 1.6-1.7 (m, 4H, H-2' and H-10'), 2.18 (m, 2H, H-11'), 3.23 ("t", 1H, J ~ 8 Hz, H-2), 3.3-3.4 (m, 3H, H-3, H-4 and H-5), 3.59 (m, 1H, H-1'a), 3.70 (dd, 1H, $J_{6\text{a},6\text{b}} = 11.9$ Hz, J_{5,6b} = 5.2 Hz, H-6a), 3.8-4.0 (m, 2H, H-6b and H-1'b), 4.31 (d, 1H, $J_{1,2} = 7.8$ Hz, H-1). ^{13}C NMR (100 MHz, CD₃OD) δ /ppm 21.3 (C-10'), 27.1 (C-3'), 30.1-30.9 (C-2', C-4' to C-9'), 31.9 (t, J = 22 Hz, C-11'), 62.9 (C-6), 70.9 (C-1'), 71.9 (C-4), 75.2 (C-2), 77.9 (C-5), 78.3 (C-3), 104.5 (C-1). ^{19}F NMR (282 MHz, CD₃OD) δ /ppm -81.3 (CF₃), -114.9 (CF₂), -122.5 (CF₂), -

123.4 (CF₂), -124.1 (CF₂), -126.7 (CF₂). Anal. calcd. for C₂₃H₃₃F₁₃O₆: C 42.34, H 5.10. Found: C 42.29, H 5.03. HR-MS of [M+Na]⁺ m/z: Calcd. 675.1967, Found. 675.1961.

12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,19-Heptadecafluorononadecyl-β-D-glucopyranoside (8f): White solid; mp: 117-118 °C; mp(DSC): 115.51±1.99 °C, 188.19±0.82 °C; Yield, 96 %; ¹H NMR (400 MHz, CD₃OD): δ/ppm 1.3-1.4 (m, 14H, 7×CH₂), 1.5-1.7 (m, 4H, H-2' and H-10'), 2.14 (m, 2H, H-11'), 3.17 ("t", 1H, J ~ 8.0 Hz, H-2), 3.2-3.4 (m, 3H, H-3, 4 and 5, overlapped with residue proton of CD₃OD), 3.55 (m, 1H, H-1'a), 3.67 (dd, 1H, J_{6a,6b} = 11.9 Hz, J_{5,6a} = 5.4 Hz, H-6a), 3.8-4.0 (m, 2H, H-6b and H-1'b), 4.25 (d, 1H, J_{1,2} = 7.8 Hz, H-1). ¹³C NMR (100 MHz, CD₃OD) δ/ppm 27.1 (C-3'), 30.1-30.9 (C-2', C-4' to C-9'), 63.0 (C-6), 71.0 (C-1'), 71.9 (C-4), 75.3 (C-2), 78.0 (C-5), 78.3 (C-3), 104.5 (C-1). ¹⁹F NMR (282 MHz, CD₃OD) δ/ppm -81.0 (CF₃), -113.7 (CF₂), -121.4 (3×CF₂), -122.2 (CF₂), 122.9 (CF₂), 125.7 (CF₂). Anal. calcd. for C₂₅H₃₃F₁₇O₆: C 39.90, H 4.42. Found: C 40.12, H 4.50. HR-MS of [M+Na]⁺ m/z: Calcd. 775.1903, Found. 775.1906.

Hexadecyl-β-D-glucopyranoside (9b): White powder; mp: 73-74 °C (Lit.: 73-75 °C²); mp(DSC): 68.43±1.07 °C, 151.78±4.65 °C; Yield, 97 %; ¹H NMR (300 MHz, CD₃OD): δ/ppm 0.90 (m, 3H, J = 6.9 Hz, H-16'), 1.3-1.4 (m, 26H, 13×CH₂), 1.62 (m, 2H, H-2'), 3.16 ("t", 1H, J ~ 8.7 Hz, H-2), 3.25-3.43 (m, 3H, H-3, 4 and 5, overlapped with residue proton of CD₃OD), 3.54 (m, 1H, H-1'a), 3.66 (dd, 1H, J_{6a,6b} = 12.0 Hz, J_{5,6a} = 5.2 Hz, H-6a), 3.8-4.0 (m, 2H, H-6b and H-1'b), 4.24 (d, 1H, J_{1,2} = 7.7 Hz, H-1). ¹³C NMR (75 MHz, CD₃OD) δ/ppm 14.5 (C-16'), 23.7 (C-15'), 27.1 (C-3'), 30.4-30.9 (C-2', C-4' to C-

13'), 33.0 (C-14'), 62.9 (C-6), 71.0 (C-1'), 71.8 (C-4), 75.2 (C-2), 77.9 (C-5), 78.3 (C-3), 104.4 (C-1). Anal. calcd. for C₂₂H₄₄O₆: C 65.31, H 10.96. Found: C 65.61, H 10.96. HR-MS of [M+Na]⁺ m/z: Calcd. 427.3036, Found. 427.3022.

Octadecyl-β-D-glucopyranoside (9c): White powder; mp: 82-83 °C (Lit.: 120 °C¹³); mp(DSC): 68.96±0.03 °C, 84.06±0.10 °C, 149.51±0.55 °C (Lit.: transitions at 71.1, 86.6, 92.9 and 145.8 °C⁴); Yield, 92 %; ¹H NMR (300 MHz, CD₃OD): δ/ppm 0.90 (m, 3H, J = 6.9 Hz, H-18'), 1.2-1.4 (m, 30H, 15×CH₂), 1.61 (m, 2H, H-2'), 3.12 ("t", 1H, J ~ 8.1 Hz, H-2), 3.2-3.4 (m, 3H, H-3, 4 and 5, overlapped with residue proton of CD₃OD), 3.53 (m, 1H, H-1'a), 3.63 (dd, 1H, J_{6a,6b} = 11.7 Hz, J_{5,6a} = 4.2 Hz, H-6a), 3.7-3.9 (m, 2H, H-6b and H-1'b), 4.23 (d, 1H, J_{1,2} = 7.7 Hz, H-1). ¹³C NMR (75 MHz, CD₃OD) δ/ppm 14.7 (C-18'), 23.7 (C-17'), 27.1 (C-3'), 30.3-30.9 (C-2', C-4' to C-15'), 33.0 (C-16'), 62.9 (C-6), 70.7 (C-1'), 71.8 (C-4), 75.1 (C-2), 78.0 (C-5), 78.3 (C-3), 104.4 (C-1). Anal. calcd. for C₂₄H₄₈O₆: C 66.63, H 11.18. Found: C 66.46, H 11.18. HR-MS of [M+Na]⁺ m/z: Calcd. 455.3373, Found. 455.3365.

Heptadecyl-β-D-glucopyranoside (9e): White powder; mp: 81-83 °C; mp(DSC): 71.01±0.67°C, 85.45±0.96 °C, 149.53±0.18 °C; Yield, 97 %; ¹H NMR (300 MHz, CD₃OD): δ/ppm 0.90 (m, 3H, J = 6.9 Hz, H-17'), 1.2-1.4 (m, 28H, 14×CH₂), 1.62 (m, 2H, H-2'), 3.15 ("t", 1H, J ~ 8.3 Hz, H-2), 3.2-3.4 (m, 3H, H-3, 4 and 5, overlapped with residue proton of CD₃OD), 3.54 (m, 1H, H-1'a), 3.66 (dd, 1H, J_{6a,6b} = 11.8 Hz, J_{5,6a} = 5.3 Hz, H-6a), 3.8-4.0 (m, 2H, H-6b and H-1'b), 4.24 (d, 1H, J_{1,2} = 7.7 Hz, H-1). ¹³C NMR (75 MHz, CD₃OD) δ/ppm 14.6 (C-17'), 23.7 (C-16'), 27.1 (C-3'), 30.4-30.9 (2', 4'~14'),

33.0 (C-15'), 62.9 (C-6), 71.0 (C-1'), 71.8 (C-4), 75.2 (C-2), 77.9 (C-5), 78.2 (C-3), 104.4 (C-1). Anal. calcd. for C₂₃H₄₆O₆: C 65.99, H 11.08. Found: C 65.93, H 11.05. HR-MS of [M+Na]⁺ m/z: Calcd. 441.3192, Found. 441.3177.

Nonadecyl- β -D-glucopyranoside (9f): White powder; mp: 88-89 °C; mp(DSC): 91.90±0.52 °C, 145.49±0.07 °C; Yield, 93 %; ¹H NMR (400 MHz, CD₃OD): δ/ppm 0.90 (t, 3H, J = 6.9 Hz, H-19'), 1.2-1.4 (m, 32H, 16×CH₂), 1.62 (m, 2H, H-2'), 3.17 ("t", 1H, J ~ 7.8 Hz, H-2), 3.2-3.4 (m, 3H, H-3, 4 and 5, overlapped with residue proton signal of CD₃OD), 3.55 (m, 1H, H-1'a), 3.67 (dd, 1H, J_{6a,6b} = 11.8 Hz, J_{5,6a} = 5.5 Hz, H-6a), 3.8-3.9 (m, 2H, H-6b and H-1'b), 4.25 (d, 1H, J_{1,2} = 7.7 Hz, H-1). ¹³C NMR (100 MHz, CD₃OD) δ/ppm 14.4 (C-19'), 23.7 (C-18'), 27.1 (C-3'), 30.4-30.9 (C-2', C-4' to C-16'), 33.1 (C-17'), 63.0 (C-6), 71.0 (C-1'), 71.9 (C-4), 75.3 (C-2), 77.9 (C-5), 78.3 (C-3), 104.5 (C-1). Anal. calcd. for C₂₅H₅₀O₆: C 67.22, H 11.28. Found: C 67.45, H 11.41. HR-MS of [M+Na]⁺ m/z: Calcd. 469.3505, Found. 469.35.9.

References

- 1 R. Hori and Y. Ikegami, *Yakugaku Zasshi*, 1959, **79**, 80.
- 2 F. Wilhelm; S. K. Chatterjee; B. Rattay; P. Nuhn; R. Benecke and J. Ortwein, *Liebigs Ann.*, 1995, 1673.
- 3 Z. Li; L. Cai and M. Cai, *Synth. Commun.*, 1992, **22**, 2121.
- 4 V. Vill; H. M. von Minden; M. H. J. Koch; U. Seydel and K. Brandenburg, *Chem. Phys. Lipids*, 2000, **104**, 75.